Dr. Douglas Dieterich: “Even with New AbbVie Drug, Many Hepatitis C Patients Are Being Turned Away from Treatment”
Hundreds of thousands of Americans this holiday season wish for nothing more than to “slay the dragon.” That’s what they call getting rid of the hepatitis C infection raging inside them. “The dragon” saps their energy as it slowly causes cirrhosis, or scarring of the liver. Now there are ways to kill hepatitis C, or HCV infection, for good without putting people who have the disease through too much agony in the process. But these cures, which are about 90 percent effective, are expensive. Sick people aren’t getting the treatments they need due to insurance denials and other roadblocks. That angers Dr. Douglas Dieterich, Director of Outpatient Hepatology at The Mount Sinai Hospital in New York City. Learn more
Researchers Identify Potential Target for Treatment Among Patients With Type 2 Diabetes
Aug 04, 2022 View All Press Releases
Mount Sinai Researcher Receives Prestigious International Award
Jul 06, 2022 View All Press Releases
